[
  {
    "ts": null,
    "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
    "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
    "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769622420,
      "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
      "id": 138287497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
      "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options",
    "summary": "Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and disfigurementFDA Breakthrough Therapy Designation is",
    "url": "https://finnhub.io/api/news?id=7fcf4e8e98941e444e8e7f0593ab270fe91d325f84e5c0faeb3610a42a727e8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769603400,
      "headline": "Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options",
      "id": 138280863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and disfigurementFDA Breakthrough Therapy Designation is",
      "url": "https://finnhub.io/api/news?id=7fcf4e8e98941e444e8e7f0593ab270fe91d325f84e5c0faeb3610a42a727e8e"
    }
  }
]